Posts by: Magdalena Kegel

Magdalena Kegel

Magdalena is a writer with a passion for bridging the gap between the people performing research, and those who want or need to understand it. She writes about medical science and drug discovery. She holds an MS in Pharmaceutical Bioscience and a PhD — spanning the fields of psychiatry, immunology, and neuropharmacology — from Karolinska Institutet in Sweden.

August 15, 2017

Corbus to Start Phase 3 Anabasum Trial in Scleroderma Patients by Year’s End

News

Corbus Pharmaceuticals says a Phase 3 clinical trial of anabasum for diffuse cutaneous scleroderma will start in the fourth quarter of 2017, putting the treatment a step closer toward ... Read more

July 26, 2017July 26, 2017

Cytori’s Habeo Cell Therapy Appears to Benefit Scleroderma Patients with Diffuse Form of the Disease

News

Cytori Therapeutics’ Habeo Cell Therapy may be effective only in scleroderma patients who have the more severe diffuse version of the disease, a Phase 3 clinical trial indicates. The ... Read more

July 13, 2017July 13, 2017

Northwestern Researchers Find Immune Cells Link to Fibrosis, Reversing Previous Theories

News

Certain immune cells contribute to the development of fibrosis, researchers at Chicago’s Northwestern Medicine discovered in a study that might overturn the view of lung fibrosis as a disease unaffected by ... Read more

May 11, 2017May 16, 2017

Cell Therapy for Localized Scleroderma Can Reverse Fibrosis in Mice

News

A cell therapy based on injected genetically modified human skin cells and a pill that activates a protein has the capacity for breaking down fibrosis in localized scleroderma — at least ... Read more

April 27, 2017April 27, 2017

Lung Fibrosis in Scleroderma Linked to Immune System and Cell Matrix in Study

News

Factors in the innate immune system, as well as those in the extracellular matrix surrounding cells, are likely involved in the development of lung fibrosis in scleroderma patients, researchers suggest after ... Read more

April 25, 2017

Cellcept Could Be Used for Scleroderma Lung Disease, Study Suggests

News

A therapy used to prevent organ rejection in patients who have a kidney, liver or heart transplant can help people with scleroderma-associated lung disease, a study suggests. That treatment, ... Read more

March 28, 2017March 28, 2017

New Imaging Method Could Improve Pulmonary Hypertension Management in Scleroderma

News

Scleroderma patients with pulmonary arterial hypertension (PAH) who respond well to treatment have more lung artery side branches than patients who respond poorly, according to a study. A milestone ... Read more

March 16, 2017March 16, 2017

Both Fingertip and Extensor Scleroderma Digital Ulcers Show Improved Blood Flow After Vessel Dilation

News

Blood vessel-dilating treatments increase blood flow equally well in digital ulcers on fingertips and in extensor surface ulcers, which occur on the opposite side of joints. This shows that ... Read more

February 28, 2017February 28, 2017

Reasons Scleroderma-linked PAH Can Kill More Quickly than IPAH Detailed in Study

News

Patients with pulmonary arterial hypertension (PAH) linked to scleroderma have worse outcomes than those with idiopathic PAH, with survival times of less than half of iPAH patients. The difference ... Read more

February 16, 2017February 16, 2017

Immunosuppressants Only of ‘Weak’ Benefit to Diffuse Scleroderma Patients, Study Reports

News

A large study following patients in the early stages of diffuse cutaneous scleroderma showed that immunosuppressants offered only a negligible benefit for those who took them, compared to those who ... Read more